


Uncovering the hidden threat: single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer

Maxim Le Compte^a, Edgar Cardenas De La Hoz^b, Sofia Peeters^a, Felicia Rodrigues^a, Sofie Seghers^a, Abraham Lin^a, Evelien Smits^a, Geert Roeyen^{c,d}, Filip Lardon^a, Hans Prenen^{c,d}, Marc Peeters^{c,d}, Christophe Deben^a

^a. Center for Oncological Research (CORE), University of Antwerp, Belgium | ^b. Industrial Vision Lab, University of Antwerp, Belgium | ^c. Department of Oncology, Antwerp University Hospital, Belgium | ^d. Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp, Belgium


INTRODUCTION

Current hurdles:



- Complex models but **basic readouts**
- Current viability readouts (**Cell-Titer Glo**) are biased
- Basic drug metrics used (% viability)
- Difficulties in stratifying patients
- Response dynamics are not taken into account
- Growth rate differences are not taken into account

METHODS



CONCLUSION

- **Orbits**: a novel AI image analysis platform
- Our analysis is capable of stratifying patient responses
- Observable trend with clinical response
- More 3D readouts in our pipeline (under development)



Interested?

Deben, C., De La Hoz, E.C., Le Compte, M., Van Schil, P., Hendriks, J.M., Lauwers, P., Yogeswaran, S.K., Lardon, F., Pauwels, P., Rogiers, A. et al. Orbits: A high-throughput, time-lapse, and label-free drug screening platform for patient-derived 3D organoids. *bioRxiv* 2021

RESULTS




Figure 1. Representative masked images of patient-derived pancreatic cancer organoids, showing the heterogeneity in response upon treatment with 400nM gemcitabine- 80nM paclitaxel for 5 days.




Figure 2. The implementation of a normalized drug response metric (NDR) improves patient stratification.




Figure 3. PDAC organoids/cells are driven in a certain 'direction' (Invasive, apoptosis, resistant). The single organoid analysis, which includes resistant and sensitive subclones, also highly correlates with the clinical outcome